At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Apixaban +2 moredrug
Likely dose
Apixaban 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
In Brief
A Phase 2 clinical trial evaluating Apixaban, Warfarin, and 1 other intervention for Heart Failure. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1 randomization to either apixaban or warfarin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsAbbott Medical Devices
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartDec 2021
Primary CompletionOct 2023
Study CompletionNov 2023
TodayJul 2026
First PostedApr 29, 2021
Enrollment StartDec 14, 2021
Primary CompletionOct 5, 2023
Study CompletionNov 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.2 years ago
Interventions
Apixabandrug
Patients randomized to apixaban will be started on a dose of 5 mg BID.
Warfarindrug
Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.
LVAD implantdevice
Subjects will undergo HeartMate 3 LVAD implant prior to randomization